Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692319 | 0.89 | MAPT (0.47) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6699737 | 0.85 | MAPT (0.49) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6690166 | 0.82 | MAPT (0.45) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6694881 | 0.82 | MAPT (0.48) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6289002 | 0.79 | MAPT (0.49) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6810386 | 0.79 | MAPT (0.49) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6672864 | 0.77 | MAPT (0.64) | MAPTMEN1KMT2A | |
| SCHEMBL6288606 | 0.76 | MAPT (0.46) | MAPTKCNH2 | |
| SCHEMBL6780769 | 0.76 | MAPT (0.51) | MAPTKCNH2MEN1KMT2A | |
| SCHEMBL6284766 | 0.76 | MAPT (0.55) | MAPTKCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| EP-1265895-A1 | 4-OXO-1,4-DIHYDRO 1,8]NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020177604-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | VAILLANCOURT VALERIE A (US) | 2002-11-28 | — | — | US | claimed |
| US-6451811-B2 | HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-09-17 | — | — | US | claimed |
| US-20020019413-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | claimed |
| WO-2001074816-A1 | 4-OXO-1,4-DIHYDRO[1,8]NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-11 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| US-6693114-B2 | N-(4-CHLOROBENZYL)-6-(3-HYDROXY-1-PROPYNYL)-1-7-DIMETHYL-4-OXO-1,4 -DIHYDRO(1,8) NAPHTHYRIDINE-3-CARBOXAMIDE FOR EXAMPLE; INHIBITING VIRAL DNA POLYMERASE; TREATING HERPES VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2004-02-17 | — | — | US | disclosed |
| EP-1265895-A1 | 4-OXO-1,4-DIHYDRO 1,8]NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020177604-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | VAILLANCOURT VALERIE A (US) | 2002-11-28 | — | — | US | disclosed |
| US-6451811-B2 | HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-20020019413-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2001074816-A1 | 4-OXO-1,4-DIHYDRO[1,8]NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019413-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | IRF3, ZC3HAV1, EIF2AK2 | MAPT 4263/4885KCNH2 1345/4885MEN1 3288/4885 |
| US-20020177604-A1 | 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents | IRF3, ZC3HAV1, EIF2AK2 | MAPT 4263/4885KCNH2 1345/4885MEN1 3288/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | MAPT 4862/4885KCNH2 4046/4885MEN1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.